TheEdgeResearch
Home / Stocks / WUXIF

WuXi AppTec Co., Ltd. (WUXIF)

OTC Healthcare Medical - Diagnostics & Research
$20.78 ▲ +0.00%
Market Cap
$62.00B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
0.46
52-Wk Range
7.34-22.7
CEO
Ge Li
Country
CN
Currency
USD

WuXi AppTec Co., Ltd. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Shanghai, SH, CN. The stock last traded at $20.78, up 0.00% on the session, giving a market capitalisation of $62.00B. On trailing twelve-month figures it carries a trailing P/E of 21.04, a net margin of 40.5%. Its beta of 0.46 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
21.04
Price / Sales
7.35
Price / Book
5.55
EV / EBITDA
12.57
Gross margin
52.0%
Operating margin
42.4%
Net margin
40.5%
Return on equity
Debt / equity
0.18
Current ratio
2.54
Dividend yield
1.2%
Payout ratio
31.5%
Company profile
Exchange
Other OTC
Employees
33,834
IPO date
2020-03-17
Headquarters
Shanghai, SH, CN
About WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd., an investment holding firm, specializes in providing a full spectrum of research, development, and manufacturing services. The company's expertise is leveraged globally to facilitate the discovery, advancement, and production of both small molecule pharmaceuticals and innovative cell and gene therapies. Its operational reach extends throughout the People's Republic of China, across the broader Asian continent, within the United States, and across Europe. The organization is structured into six distinct divisions: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and a collective "Others" segment. WuXi AppTec offers comprehensive contract research, development, and manufacturing (CRDMO) capabilities, supporting new drug candidates from their initial discovery phases all the way to commercial launch. This support covers a diverse array of synthetic molecular compounds, such as small molecules, oligonucleotides, peptides, and intricate conjugates. Additionally, the company delivers biology services and solutions that underpin standalone or integrated projects, ranging from target identification to candidate selection and subsequent clinical progression. The firm also provides streamlined testing services for drugs and medical devices, spanning from preclinical evaluation to full-scale clinical trials. It further distinguishes itself by offering an integrated, end-to-end solution specifically designed to expedite the market entry of cell and gene therapies. Complementary services include drug discovery assistance for pharmaceutical and biotechnology clients, as well as comprehensive clinical research services. Founded in the year 2000, WuXi AppTec Co., Ltd. maintains its headquarters in Shanghai, People's Republic of China.

Comparable companies

WuXi AppTec Co., Ltd. is most often compared with the following Healthcare names:

CHALFDSKYFDSNKYHLNCFHOCPFIPSEYLZAGFLZAGYRSMDFUCBJY
More research on WUXIF
WUXIF technical analysis WUXIF TheEdge Score Compare against peers
Open full interactive analysis & DCF →